10 patent families. 364K lines. Self-improving daily.
Meta-learning (MAML) inside drug scoring. Adapts to new target classes in 1 gradient step. 28-dim dual scorer. Self-corrects from outcomes. Governed self-modification.
TF activity inference → discordance detection → EGAO authority scoring → therapeutic hypothesis generation → strategy-conditioned molecules. +21% NPEAD uplift.
Every docking result feeds back. Transformer fine-tuned on positives. Active learning (2 iter/job). Daily RL from Vina scores. Known actives seeding (enzalutamide, osimertinib, dabrafenib scaffolds). Confidence-weighted temperature. Model improves without human.
3D CNN pocket encoder. Real PDB profiles (16 targets). 16-dim conditioning = pocket shape + regulatory intent + NPEAD knowledge. 94% validity.
8 gates cheapest-first. External grade gate. Authority only decreases. 95% cost reduction vs naive pipelines.
Level 1: Autonomous config (bounds/delta/cooldown). Level 2: Self-generated PRs with evidence bundles. Never touches main.
145 genes from TCGA. De novo + repurposing + CDx + cross-cancer scan. 4 revenue streams. RO-Crate evidence.
Diagnoses WHY molecules fail: steric clash, missing H-bonds, shape mismatch. Generates fix suggestions for next cycle.
276 nodes, 608 edges. Qdrant vectors. GCN driver/passenger (87.5%). Fused embeddings for cross-entity reasoning.
VQE binding confirmation (local/sv1/IonQ). Quantum only after classical gates pass. Cost-ordered.
| # | Differentiator | Why It Matters |
|---|---|---|
| 1 | NPEAD learn-to-learn | Adapts instantly to new targets — no retraining |
| 2 | Governed self-improvement | Autonomous but safe — regulated environments need this |
| 3 | Closed-loop generation | Gets better every day without human intervention |
| 4 | Monotone cost escalation | 95% cheaper than brute-force approaches |
| 5 | Full evidence chain | Every decision traceable — patent and regulatory ready |
| 6 | End-to-end multi-cancer | 4 revenue streams from one system |
| 7 | Strategy-conditioned generation | Molecules have therapeutic intent from first atom |